Brenig Therapeutics Raises $65 Million in Series A Funding to Advance Pre-Clinical Pipeline for Parkinson’s Disease
Wednesday, July 24, 2024
Brenig Therapeutics Inc., a trailblazer in neurology-focused drug development utilizing an AI/ML-based discovery platform, has successfully completed a $65 million Series A funding round. The round was led by New Enterprise Associates (NEA), with participation from another US-based healthcare investor and existing investors including OrbiMed, Torrey Pines Investments, and BioGeneration Ventures. Ed Mathers, Partner at NEA, will join the company’s Board of Directors as part of this investment.
Iain Dukes MA DPhil, Chairman of Brenig, commented on the funding: "This capital will help us advance our mission to develop therapies for Parkinson’s disease that stand out in the field."
Ed Mathers highlighted the progress made by Brenig, stating, "The team at Brenig has made significant strides since its start. We are confident that their approach could lead to superior treatments for Parkinson’s disease. NEA is excited to support Brenig as it enters this next stage of development."
The funds will be allocated to progressing BT-267 through studies with healthy volunteers and into proof-of-concept trials in idiopathic Parkinson's disease patients. Brenig also plans to explore further innovative approaches for treating Parkinson’s disease.
BT-267 is a small molecule LRRK2 inhibitor designed for optimal pharmacokinetic performance, ensuring high and sustained brain exposure with minimal peripheral exposure. This aims to enhance therapeutic efficacy while reducing on-target, off-tissue toxicity. The molecule displays exceptional kinome selectivity, avoiding off-target effects, and has demonstrated a favorable safety profile in ongoing GLP studies.
Source: prnewswire.com
